Drug Profile
Cadonilimab - Akeso Biopharma
Alternative Names: AK-104Latest Information Update: 22 Apr 2024
Price :
$50
*
At a glance
- Originator Akeso Biopharma
- Developer Akeso Biopharma; Chipscreen Biosciences; Sun Yat-Sen University; The Third Affiliated Hospital of Soochow University
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Cervical cancer
- Preregistration Gastric cancer; Oesophageal cancer
- Phase III Liver cancer; Non-small cell lung cancer
- Phase II Nasopharyngeal cancer; Rectal cancer; Renal cell carcinoma; Solid tumours
- Phase I/II Malignant melanoma; Pancreatic cancer; Peripheral T-cell lymphoma; Small cell lung cancer
Most Recent Events
- 22 Apr 2024 Akeso Biopharma plans a phase III trial for Liver cancer (Combination therapy, In adults, In the elderly) in China (IV) in July 2024 (NCT06371157)
- 08 Apr 2024 Updated efficacy data from the phase III COMPASSION-15 trial in Gastric cancer released by Akeso Biopharma
- 02 Apr 2024 Akeso plans a phase III trial for Adenocarcinoma (Combination therapy, Second-line therapy or greater, Metastatic disease, Inoperable/Unresectable, Late-stage disease) (IV) in May 2024 (NCT06341335)